Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data

[11] Nink K(1993)The functional assessment of cancer therapy scale: development and validation of the general measure J. Clin. Oncol. 11 570-579

[12] McGauran N(1997)Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument Urology 50 920-928

[13] Wieseler B(2010)International development of the patient-reported outcome indices for multiple sclerosis (PRIMUS) Value Health 13 946-951

[14] Leopold C(1997)Reliability and validity of the functional assessment of cancer therapy—breast quality-of-life instrument J. Clin. Oncol. 15 974-986

[15] Vogler S(2009)A short history of health technology assessment in Germany Int. J. Technol. Assess. Health Care 25 112-119

[16] Mantel-Teeuwisse AK(2013)Das Arzneimittelmarktneuordnungsgesetz (AMNOG) in der Praxis—erste Erfahrungen, Kritikpunkte und Weiterentwicklungsmöglichkeiten Gesundheitsökonomie & Qualitätsmanagement 18 213-220

[17] de Joncheere K(2014)Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation Eur. J. Health Econ. 15 577-589

[18] Leufkens HGM(undefined)undefined undefined undefined undefined-undefined

[19] Laing R(undefined)undefined undefined undefined undefined-undefined

[20] Ahmed S(undefined)undefined undefined undefined undefined-undefined

[11] Nink K(1993)The functional assessment of cancer therapy scale: development and validation of the general measure J. Clin. Oncol. 11 570-579

[12] McGauran N(1997)Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument Urology 50 920-928

[13] Wieseler B(2010)International development of the patient-reported outcome indices for multiple sclerosis (PRIMUS) Value Health 13 946-951

[14] Leopold C(1997)Reliability and validity of the functional assessment of cancer therapy—breast quality-of-life instrument J. Clin. Oncol. 15 974-986

[15] Vogler S(2009)A short history of health technology assessment in Germany Int. J. Technol. Assess. Health Care 25 112-119

[16] Mantel-Teeuwisse AK(2013)Das Arzneimittelmarktneuordnungsgesetz (AMNOG) in der Praxis—erste Erfahrungen, Kritikpunkte und Weiterentwicklungsmöglichkeiten Gesundheitsökonomie & Qualitätsmanagement 18 213-220

[17] de Joncheere K(2014)Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation Eur. J. Health Econ. 15 577-589

[18] Leufkens HGM(undefined)undefined undefined undefined undefined-undefined

[19] Laing R(undefined)undefined undefined undefined undefined-undefined

[20] Ahmed S(undefined)undefined undefined undefined undefined-undefined